Metamizole
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03990129 | Sep → Oct 2018 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 1 | NCT01995006 | Jan → Apr 2014 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02660177 | Apr 2016 → Dec 2017 | — | University Children's Hospital Basel | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07682558 | Oct 2026 → Nov 2029 expected | — | University Hospital, Basel, Switzerland | Not yet recruiting | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT07024199 | Sep 2025 → Jun 2027 expected | acute pancreatitis | Medical University of Warsaw | Recruiting | No outcome recorded |
| Phase 4 | NCT02686021 | Feb 2016 → Apr 2021 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 4 | NCT02181920 | Mar → Nov 2000 | — | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 4 | NCT02184260 | Dec 1998 → May 2002 | ischemic stroke | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase not applicable2 trials · 1 met primary | ||||||
| — | NCT07384013 | Nov 2025 → Dec 2027 expected | blood coagulation disease, cancer-related condition | Rambam Health Care Campus | Recruiting | No outcome recorded |
| — | NCT05831761 | Sep 2009 → Oct 2011 | — | University Medical Centre Ljubljana | Completed | Met primary |
| Comparator or background therapy16 trials | ||||||
| Phase 1 | NCT04621253 Comparator | Apr → Oct 2020 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 3 | NCT02662660 Background | Jan 2012 → Dec 2015 | — | Hospital General Universitario Elche | Completed | No outcome recorded |
| Phase 4 | NCT06878014 Comparator | Mar 2025 → Jun 2026 overdue | — | Medical University of Silesia | Recruiting | No outcome recorded |
| Phase 4 | NCT04111315 Comparator | Dec 2019 → Dec 2025 | — | Insel Gruppe AG, University Hospital Bern | Unknown | No outcome recorded |
| Phase 4 | NCT04691726 Comparator | Jan 2019 → Jun 2022 | abdominal aortic aneurysm, aortic atherosclerosis | Łukasz Krzych | Completed | No outcome recorded |
| Phase 4 | NCT03404908 Background | Feb 2018 → Jan 2019 | — | Medical University of Lublin | Completed | No outcome recorded |
| Phase 4 | NCT02445599 Background | Apr 2014 → Apr 2016 | lung disorder | University of Debrecen | Completed | No outcome recorded |
| — | NCT07558226 Comparator | May 2026 → Nov 2027 expected | — | Fundacio Puigvert | Recruiting | No outcome recorded |
| — | NCT05270434 Background | Mar → Oct 2025 | chronic pancreatitis | Changhai Hospital | Completed | No outcome recorded |
| — | NCT07337135 Background | Oct 2023 → Apr 2024 | morbid obesity | Hospital dos Lusíadas | Completed | No outcome recorded |
| — | NCT04685291 Comparator | Apr 2021 → Jun 2023 | — | Eckehart SCHÖLL | Completed | No outcome recorded |
| — | NCT04703257 Comparator | Feb 2021 → Dec 2022 | — | Jessa Hospital | Completed | No outcome recorded |
| — | NCT04082728 Comparator | Nov 2019 → Feb 2022 | — | Jessa Hospital | Completed | No outcome recorded |
| — | NCT02971475 Background | Nov 2016 → May 2019 | chronic pancreatitis | Changhai Hospital | Unknown | No outcome recorded |
| — | NCT03956446 Background | Sep 2014 → Dec 2027 expected | tick-borne encephalitis | University Medical Centre Ljubljana | Recruiting | No outcome recorded |
| — | NCT02463942 Background | Sep 2014 → Sep 2020 | tick-borne encephalitis | University Medical Centre Ljubljana | Unknown | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 27 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Metamizole | “Group B will receive a dose of Paracetamol B. Braun/Paracetamol Kabi intravenously 15 mg/kg body weight (maximum 1000 mg/dose) and Metamizol-SF/Metamizole Kabi/Pyralgin...” NCT07024199 ↗25“Patients will receive symptomatic therapy with antipyretics, analgetics, antiemetics, and parenteral hydration: metamizole, Analgin®, paracetamol, Lekadol®, thiethylperazine,...” NCT02463942 ↗ “Patients will receive symptomatic therapy with antipyretics, analgetics, antiemetics, and parenteral hydration: metamizole, Analgin®, paracetamol, Lekadol®, thiethylperazine,...” NCT03956446 ↗ “oral pain medication in patients younger than 70 years: Ibuprofen 400mg (1-1-1) AND Metamizole 500mg (max. 2 tbl. every 6 hours)” NCT04685291 ↗ “Continous postoperative infusion of tramadol 300 mg and metamizole 2,5 g (in 500 ml 0.9% NaCl, rate of infusion 40 ml/h)” NCT05831761 ↗ “Postoperative analgesia includes paracetamol + ketorolac/parecoxib + metamizole,” NCT07337135 ↗ “Single dose of 1000 mg metamizole, 1h after the last inhibitor or placebo intake” NCT04621253 ↗ “Metamizole: 1g/8h iv” NCT07558226 ↗ “Metamizole” NCT04111315 ↗ |
| Known as | Dipyrone | “Efficacy of Non-opioid Drugs in Addition to Opioid Therapy for Cancer Pain Management: a Double-blind, Randomized, Three Arm, Placebo Controlled Trial Assessing the Key...” NCT07682558 ↗4“Dose evaluation of intravenous metamizole (dipyrone) in infants and children: a prospective population pharmacokinetic study.” PMID 31388703 ↗ Aug 2019 “Metamizole (dipyrone) is a non-opioid compound with strong analgesic, antipyretic, and spasmolytic effects.” NCT04703257 ↗ “Metamizole (dipyrone) is a non-opioid compound with strong analgesic, antipyretic and spasmolytic effects.” NCT04082728 ↗ “Pharmacokinetic Interactions of Metamizole (Dipyrone) in Healthy Subjects” NCT03990129 ↗ |
| Known as | Metamizol-SF | “Group B will receive a dose of Paracetamol B. Braun/Paracetamol Kabi intravenously 15 mg/kg body weight (maximum 1000 mg/dose) and Metamizol-SF/Metamizole Kabi/Pyralgin...” NCT07024199 ↗ |
| Known as | Metamizole Kabi | “Group B will receive a dose of Paracetamol B. Braun/Paracetamol Kabi intravenously 15 mg/kg body weight (maximum 1000 mg/dose) and Metamizol-SF/Metamizole Kabi/Pyralgin...” NCT07024199 ↗ |
| Known as | Metamizole-sodium | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02445599 ↗ |
| Known as | Novalgin | “Metamizole (Novalgin® Oblong tablets 0,5 g) orally three times daily 2 capsules for 4 days followed by an as needed regimen (days 4 - 42).” NCT04111315 ↗ |
| Known as | Pyralgin | “Group B will receive a dose of Paracetamol B. Braun/Paracetamol Kabi intravenously 15 mg/kg body weight (maximum 1000 mg/dose) and Metamizol-SF/Metamizole Kabi/Pyralgin...” NCT07024199 ↗ |
| Action | Inhibit | “better renal tolerability of metamizole possibly due to less potent COX-inhibition” NCT01995006 ↗ |
| Route | Oral | “Oral Metamizole or Naproxen” NCT01995006 ↗ |